Abata Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Abata Therapeutics's estimated annual revenue is currently $9.6M per year.(i)
  • Abata Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Abata Therapeutics has 62 Employees.(i)
  • Abata Therapeutics grew their employee count by 13% last year.

Abata Therapeutics's People

NameTitleEmail/Phone
1
SVP, Finance and FacilitiesReveal Email/Phone
2
VP, Program Management and Pipeline StrategyReveal Email/Phone
3
Associate Director, Non-Clinical and Translational Development LeadReveal Email/Phone
4
Chief People OfficerReveal Email/Phone
5
Chief Scientific OfficerReveal Email/Phone
6
Chief Technical OfficerReveal Email/Phone
7
Senior Director - Head Clinical SciencesReveal Email/Phone
8
Sr. Director, Process DevelopmentReveal Email/Phone
9
Chief Medical OfficerReveal Email/Phone
10
Senior Director Intellectual Property and ContractsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Abata Therapeutics?

keywords:N/A

N/A

Total Funding

62

Number of Employees

$9.6M

Revenue (est)

13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Abata Therapeutics News

2022-04-13 - Movers & Shakers, April 8 | BioSpace

Abata Therapeutics: Abata formed its scientific advisory board chaired by Diane Mathis, cofounder of Abata. Board members include John...

2022-04-06 - Abata Announces Formation of Advisory Board Comprised of ...

BOSTON--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.6M6213%N/A
#2
$3.5M623%N/A
#3
$15M625%N/A
#4
$8.1M625%N/A
#5
$9.8M62-9%N/A